Results 21 to 30 of about 3,056 (181)

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Monoclonal antibodies (mAbs) for Alzheimer's disease (AD) represent major therapeutic advances, but their economic value is uncertain.
Tuyet Thao Nguyen, Bozhidar T. Chakalov, Megan Van Noord, Charles DeCarli, Jeffrey S. Hoch   +4 more
doaj   +2 more sources

The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer’s Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective [PDF]

Diagnostics
Amyloid positron emission tomography (PET) has become a critical tool in the diagnosis and treatment of Alzheimer’s disease (AD). The Centiloid (CL) scale, a tracer/scanner-independent, standardized quantification unit introduced in 2015, transforms ...
Houman Sotoudeh, Mohammadreza Alizadeh
doaj   +2 more sources

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +2 more sources

Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model. [PDF]

PLoS Computational Biology, 2022
With the recent approval by the FDA of the first disease-modifying drug for Alzheimer's Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk.
Wenrui Hao, Suzanne Lenhart, Jeffrey R Petrella   +2 more
doaj   +2 more sources

Eligibility for anti‐amyloid treatment in a multiethnic community‐based study [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Introduction The approval of anti‐amyloid monoclonal antibodies (mAbs), including lecanemab and donanemab, represents a significant advance in disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD).
Lydia Trudel, Joseph Therriault, Arthur C. Macedo, Karin L. Meeker, Meredith N. Braskie, Arthur W. Toga, Serge Gauthier, Paolo Vitali, Suzanne E. Schindler, Sid E. O'Bryant, Pedro Rosa‐Neto   +10 more
doaj   +2 more sources

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's disease (AD) will benefit more patients.
Hugo Geerts, Silke Bergeler, Mike Walker, Rachel H. Rose, Piet H. van derGraaf   +4 more
doaj   +2 more sources

Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience [PDF]

Alzheimer’s Research & Therapy
Background Anti-amyloid monoclonal antibodies are entering clinical practice for early symptomatic Alzheimer’s disease (AD), but European real-world data on feasibility, safety, and biomarker monitoring remain limited.
Federica Agosta, Giordano Cecchetti, Edoardo G. Spinelli, Alma Ghirelli, Giulia Rugarli, Stefano Pisano, Federico Coraglia, Elisa Canu, Veronica Castelnovo, Elisa Sibilla, Anna Gilioli, Chiara Tripodi, Fabiola Freri, Alessandra Bianchi, Paolo Vezzulli, Sonia Calloni, Andrea Falini, Ana Maria Samanes Gajate, Andrea Panzacchi, Gino Pepe, Camilla Ferri, Arturo Chiti, Massimo Filippi   +22 more
doaj   +2 more sources

Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease

Arquivos de Neuro-Psiquiatria
Two antiamyloid monoclonal antibodies (mAbs), lecanemab and donanemab, were recently launched for treatment of Alzheimer's disease (AD). These mAbs remove amyloid protein from the brain and cause statistically significant improvement in cognitive ...
Ricardo Nitrini, Adalberto Studart-Neto
doaj   +2 more sources

The regulatory rollercoaster continues—EMA refuses donanemab

The Lancet
In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval followed a nearly 2-year review process that involved multiple rounds of evaluation, initial rejections, formal appeals, and ultimately a reversal of the ...
De Strooper, Bart, Haass, Christian, Hardy, John, Zetterberg, Henrik   +3 more
openaire   +5 more sources

Recomendaciones de uso de donanemab

Acta Neurológica Colombiana
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide.
Paulina Elizabeth Bombón-Albán, Tatiana Gabriela Aldaz-López   +1 more
doaj   +2 more sources